Status:
WITHDRAWN
Coronary Vasomotor Response After Riociguat Exposure
Lead Sponsor:
Bayer
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin...
Eligibility Criteria
Inclusion
- Male and female patients with coronary artery disease
Exclusion
- Patents with coronary artery disease with \>/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery \[LAD\], left circumflex coronary artery \[LCX\] or right coronary artery \[RCA\]) undergoing cardiac catheterization
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01165931
Start Date
May 1 2012
End Date
January 1 2013
Last Update
October 23 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston, Massachusetts, United States, 02114